Gene licensing stifles R&D

Privatizing research findings may slow innovation, study finds

Making scientific information proprietary may quash innovation, a survey of genes discovered during the last decade concludes. The analysis found that genes discovered by the biotechnology company Celera — and protected as intellectual property for up to two years — were less likely to be studied by researchers and the developers of drugs and diagnostic tests than were genes that remained in the public domain.